Semaglutide Dosage Calculator
Semaglutide is sold as three different products with three different dose schedules, and mixing them up is the most common mistake people make when planning their titration. Ozempic (weekly injection for type 2 diabetes) tops out at 2.0 mg, Wegovy (weekly injection for weight management) climbs to 2.4 mg, and Rybelsus (daily tablet for type 2 diabetes) steps through 3, 7, and 14 mg. Pick your product, enter your current treatment week, and this calculator shows your scheduled dose, when the next increase comes, how many weeks remain to the maintenance dose, and the cumulative dose you have taken so far. If you are tracking the diet side of weight management, pair this with our keto calorie calculator and carb counter.
Quick Answer
The three label schedules side by side
All three products contain semaglutide, but they are not the same medicine in practice. Ozempic pens deliver fixed weekly doses for type 2 diabetes; Wegovy pens deliver a higher escalation for weight management; Rybelsus is a once-daily oral tablet taken on an empty stomach with a small amount of water. The tablet and injection forms are not substitutable milligram for milligram.
| Treatment weeks | Ozempic (weekly) | Wegovy (weekly) | Rybelsus (daily) |
|---|---|---|---|
| 1-4 | 0.25 mg | 0.25 mg | 3 mg |
| 5-8 | 0.5 mg | 0.5 mg | 7 mg |
| 9-12 | 1.0 mg | 1.0 mg | 14 mg |
| 13-16 | 2.0 mg (max) | 1.7 mg | 14 mg |
| 17+ | 2.0 mg | 2.4 mg (maintenance) | 14 mg |
The 0.25 mg starting dose is a tolerability dose, not a therapeutic one; the label states it is intended for treatment initiation and is not effective for glycemic control. The slow 4-week steps exist because faster titration raises nausea and vomiting rates and drives people to quit. Many patients also hold a lower dose longer than the label if appetite suppression is already working or side effects need time to settle, which is a prescriber judgment, not a schedule failure.
Worked example: Wegovy at week 10
Week 10 falls in the 9-12 band, so the scheduled dose is 1.0 mg once weekly. Looking ahead: weeks 13-16 call for 1.7 mg, and week 17 onward is the 2.4 mg maintenance dose, so there are 7 weeks to full maintenance. Cumulative dose: 4 weeks at 0.25 (1.0 mg) + 4 weeks at 0.5 (2.0 mg) + 2 weeks at 1.0 (2.0 mg) = 5.0 mg total. The calculator shows this exact breakdown when you select Wegovy and week 10.
For comparison, the same week on Rybelsus means 14 mg daily (you reached the top step at week 9), with a cumulative 476 mg taken: 84 mg from the 3 mg weeks, 196 mg from the 7 mg weeks, and 196 mg from the first two 14 mg weeks. Tracking nutrition alongside matters at every stage: as calories drop, protein intake becomes the priority for preserving muscle, which our macronutrient calculator can help you plan, and overall progress is easiest to follow with our BMI and waist circumference calculator.
What competing calculators get wrong
The semaglutide calculator space is crowded and sloppy. The single most common error is the merged schedule: several top-ranking tools present one titration ladder, 0.25 to 0.5 to 1.0 to 1.7 to 2.4 mg, labeled “Ozempic / Wegovy,” but 1.7 mg and 2.4 mg are not Ozempic doses at all. Ozempic’s maximum is 2.0 mg. Another tool lists 7.2 mg as Wegovy’s maximum; that dose exists only in clinical trials and is not an approved maintenance dose. A third class of tools is simply stale: schedules copied before the label updates, with no Rybelsus coverage anywhere.
Our calculator’s winning moves: three separate label-accurate schedules selected by product, the exact week of the next increase, weeks remaining to maintenance, and cumulative dose to date, which no competitor we tested computes. We also cover the two questions every user asks and most tools dodge: what happens with missed doses (weekly injections missed by more than about two weeks generally require re-titration under clinician direction) and why the 0.25 mg starting dose is not expected to do anything therapeutic.
Using this calculator step by step
- Select your product. Double-check the pen or tablet label: Ozempic and Wegovy pens look similar but deliver different doses.
- Enter your current treatment week, counting from your first dose as week 1.
- Read your scheduled dose, the week of the next increase, weeks to maintenance, and cumulative dose.
- If anything differs from what your prescriber told you, follow your prescriber. The label schedule is the default, not the rule.
- If you missed doses, do not advance the schedule yourself. Ask your clinician whether to resume or re-titrate.
- Ozempic (0.25 to 2.0 mg weekly), Wegovy (0.25 to 2.4 mg weekly), and Rybelsus (3 to 14 mg daily) have different schedules. Never mix them.
- The 0.25 mg starting dose is for tolerability, not therapy. Full effect builds over 16 to 20 weeks.
- Faster escalation means more nausea and more dropouts. Slow titration is the point, not a delay.
- Missed weekly doses can require re-titration. Restart decisions belong to your prescriber.
- Compounded semaglutide is not FDA-approved and its dosing is not standardized to these label schedules.
Frequently Asked Questions
They share the same molecule and the same escalation through 1.0 mg (weeks 1-12). Then they diverge: Ozempic goes to a 2.0 mg maximum for diabetes, while Wegovy continues through 1.7 mg (weeks 13-16) to a 2.4 mg maintenance dose for weight management. You cannot substitute one product’s schedule for the other.
About 12 weeks to reach Ozempic’s 2.0 mg, 16 weeks to reach Wegovy’s 2.4 mg, and 8 weeks to reach Rybelsus’s 14 mg daily dose. Prescribers often extend the timeline by holding doses longer for tolerability, so these are minimums, not promises.
Take it as soon as you remember if it is within a few days, then resume your regular day. If more than about two weeks have passed since a weekly injection, the label advises re-titration from a lower dose, and your clinician should direct that. For Rybelsus, skip the missed tablet and take the next day’s dose; never double up.
The 0.25 mg dose exists to let your gut adjust. Semaglutide slows gastric emptying, and jumping straight to a therapeutic dose causes severe nausea and vomiting in many people. Trials showed faster titration meaningfully increases dropout rates, so the slow ramp is evidence-based, not cautious.
Not reliably. Compounded products are not FDA-approved, their concentrations vary, and they do not follow the branded pen delivery systems these schedules assume. Dosing compounded semaglutide requires direct prescriber and pharmacist guidance; a label-based calculator cannot validate it.
Oral semaglutide has much lower bioavailability, which is why the doses look so different (14 mg daily versus 2.4 mg weekly). It must be taken on an empty stomach with a small amount of water, waiting at least 30 minutes before eating, or absorption drops sharply. The tablets are not interchangeable with the injections milligram for milligram.
Add This Calculator to Your Website
References
- U.S. National Library of Medicine. Ozempic (semaglutide) injection: FDA-approved prescribing information. DailyMed. Titration: 0.25 mg for 4 weeks, then 0.5 mg, then 1 mg, maximum 2 mg weekly. Accessed October 19, 2026.
- U.S. National Library of Medicine. Rybelsus (semaglutide) tablets: FDA-approved prescribing information. DailyMed. Titration: 3 mg daily for 30 days, then 7 mg, then 14 mg daily. Accessed October 19, 2026.
- Novo Nordisk. Wegovy (semaglutide) injection: FDA-approved prescribing information. Titration: 0.25, 0.5, 1.0, 1.7 mg at 4-week intervals, then 2.4 mg maintenance weekly. Accessed October 19, 2026.
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989-1002. STEP 1 trial: 14.9% mean weight loss at 68 weeks on 2.4 mg weekly.
- American Diabetes Association. Standards of Care in Diabetes 2026. GLP-1 receptor agonist recommendations for type 2 diabetes management. Accessed October 19, 2026.
- Davies M, et al. Semaglutide effects on glycemic control in type 2 diabetes (SUSTAIN program). JAMA. 2017;318(15):1460-1470. Glycemic efficacy across the Ozempic dose range.
- U.S. Food and Drug Administration. FDA Adverse Event Reporting System: GLP-1 gastrointestinal safety communications. Nausea and vomiting as the most common adverse reactions, mitigated by dose escalation. Accessed October 19, 2026.
- Endocrine Society. Pharmacologic management of obesity clinical practice guideline. Role of GLP-1 receptor agonists in weight management. Accessed October 19, 2026.
- U.S. National Library of Medicine. DailyMed drug label database. Source for current FDA-approved semaglutide labeling. Accessed October 19, 2026.